The Marque The Marque
The Marque
About Services Profiles Press Contact
Nicholas’ Profile > News Archive

Nicholas’ News Archive

The News Archive for Nicholas Singer

Nicholas’ News Archive

The News Archive for Nicholas Singer

Nicholas Singer

Founder & Managing Member

Purchase Capital
Miami, FL, USA
20 May 2022 | Business Wire

Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics

Comera Life Sciences Holdings, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp.

14 Mar 2022 | IntegriCo Composites

IntegriCo expands product line, restructures management

As IntegriCo continues to expand and restructure as a company, Nicholas Singer was named executive chairman responsible for day-to-day management. He expresses his excitement for future growth and benefit for the environment.

31 Jan 2022 | Bloomberg

OTR Blank-Check Company to Merge With Comera Life Sciences

Comera Life Sciences Inc. has agreed to go public through a merger with OTR Acquisition Corp., a special purpose acquisition company led by Chairman & CEO, Nicholas Singer.

12 Apr 2021 | The Journal News

Westchester lawmakers OK new Playland contract after bitter legal battle

Westchester County lawmakers approved a new contract for a company to manage Playland on Monday, after the effort to dissolve the old contract fizzled. The county Board of Legislators voted 13-4 to give a new contract to Standard Amusements. Under the new deal, Standard would take over day-to-day operations of the park on Dec. 1. 

25 Mar 2021 | Businesswire

Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the completion of the reverse merger with NTN Buzztime, Inc. Brooklyn will focus on the advancement of IRX-2, its cytokine-based compound for the treatment of various cancers, as well as opportunities in the area of gene editing/cell therapy through its option agreement with Factor Bioscience/Novellus.

Load More